The existence of primary fibrinolysis (PF) and a defined mechanistic link to the "Acute Coagulopathy of Trauma" is controversial. Rapid thrombelastography (r-TEG) offers point of care comprehensive assessment of the coagulation system. We hypothesized that postinjury PF occurs early in severe shock, leading to postinjury coagulopathy, and ultimately hemorrhage-related death. Methods: Consecutive patients over 14 months at risk for postinjury coagulopathy were stratified by transfusion requirements into massive (MT) Ͼ10 units/6 hours (n ϭ 32), moderate (Mod) 5 to 9 units/6 hours (n ϭ 15), and minimal (Min) Ͻ5 units/6 hours (n ϭ 14). r-TEG was performed by adding tissue factor to uncitrated whole blood. r-TEG estimated percent lysis was categorized as PF when Ͼ15% estimated percent lysis was detected. Coagulopathy was defined as r-TEG clot strength ϭ G Ͻ 5.3 dynes/cm 2 . Logistic regression was used to define independent predictors of PF. Results: A total of 34% of injured patients requiring MT had PF, which was associated with lower emergency department systolic blood pressure, core temperature, and greater metabolic acidosis (analysis of variance, P Ͻ 0.0001). The risk of death correlated significantly with PF (P ϭ 0.026). PF occurred early (median, 58 minutes; interquartile range, 1.2-95.9 minutes); every 1 unit drop in G increased the risk of PF by 30%, and death by over 10%. Conclusions: Our results confirm the existence of PF in severely injured patients. It occurs early (Ͻ1 hour), and is associated with MT requirements, coagulopathy, and hemorrhage-related death. These data warrant renewed emphasis on the early diagnosis and treatment of fibrinolysis in this cohort.
H emorrhagic shock and associated postinjury coagulopathy accounts for over half of deaths world-wide for patients arriving at the hospital following acute traumatic injury, [1] [2] [3] [4] [5] and this death rate has improved only marginally over the past 25 years despite the widespread adaption of damage control techniques. Previous studies from our institution [1] [2] [3] 5 as well as others 6 -9 have demonstrated that among patients presenting with postinjury massive hemorrhage, the majority succumb to refractory coagulopathy even after surgical control of their wounds. Although this syndrome, which we originally termed the "bloody vicious cycle," 2 has been recognized for over 35 years, an understanding of the pathogenesis of the hemostatic derangements associated with these findings has remained elusive, due in part to limitations of conventional coagulation testing, 10 -13 as well as a lack of rapid, point-of-care (POC) analysis of whole blood coagulation. 14 -19 Accordingly, only minimal advances have been made to directly address this issue. Recent evidence from our institution, 5 and others, 20 -24 suggests that although coagulation abnormalities have been recognized to occur early after injury, they may be independent of clotting factor deficiency. 25 In fact, evidence suggests that over one-third of multiply injured patients are coagulopathic immediately on arrival to the emergency department, based on conventional laboratory assessment. 5, 21, 22, 24 This subset of patients has been shown to harbor a substantially increased risk of subsequent multiple organ failure and death. These facts underscore the imprimatur for active pursuit of an improved understanding of early postinjury coagulopathy, which we have previously termed "acute endogenous coagulopathy," 25 although the more global term "Acute Coagulopathy of Trauma" (ACOT) has recently been advocated. 22, 24, 26, 27 Furthermore, others have attempted to identify potential mechanistic links to this process, including variations of phenotype (hemorrhagic vs. thrombotic) in processes classically described as disseminated intravascular coagulation, [27] [28] [29] or pathways attributable to alterations in the protein C anticoagulant system via thrombomodulin-thrombin interactions. [21] [22] [23] [24] 30, 31 Of note, all potential mechanisms depend significantly on a link to the process of fibrinolysis with associated poor clot strength, leading to rapid clot dissolution in the patient with severe injuries and shock.
Recent experience with thrombelastography (TEG) in our institution (J. L. Kashuk et al, unpublished data), 32, 33 and others, 15,16,18,19,34 -39 suggests that this technology provides a realtime, viscoelastic analysis of the blood clotting process, which could serve as a template for clinical applications of the cell-based model of coagulation. TEG assesses clot strength from initial fibrin formation, to clot dissolution via fibrinolysis, and is the only single test available, which can simultaneously provide analyses of the important and essential balance of the 2 opposing components of hemostasis, namely thrombosis and fibrinolysis. Furthermore, TEG is currently the only available test capable of rapidly identifying the presence and quantifying the degree of fibrinolysis in vitro.
The purpose of this study was to determine whether fibrinolysis occurs in severely injured patients at risk for ACOT. We hypothesized that postinjury fibrinolysis could be identified by TEG, occurs early in severe shock, and is associated with poor clot strength. We further theorized that fibrinolysis is integral in the pathogenesis of ACOT, leading to hemorrhage-related death.
METHODS
An analysis of our prospectively collected trauma database was performed for 61 consecutive patients at risk for postinjury coagulopathy admitted to our American College of Surgeons certified and State verified regional level 1 trauma center. Inclusion criteria were any patient presenting to our institution with traumatic injuries requiring transfusion. We defined massive transfusions as a time frame of the first 6 hours, as opposed to 24 hours, because we have previously identified this time frame to be an independent risk factor for multiple organ failure. 40 We then stratified transfusions by volume of packed RBCs administered as follows: massive (Ն10 units/6 h), moderate (Ն5 to Յ9 units/6 h), and minimal (Ն5 units/6 hours). Patients who died of an associated head injury were excluded from this study, as were emergency department deaths, and patients with pre-existing liver disease. These studies were performed as part of a pilot investigation following implementation of point-of-care (POC) rapid thrombelastography (r-TEG) technology in our institution. Two computerized TEG Coagulation Analyzers (TEG model 5000, Hemoscope, Niles, IL) were employed. Quality control checks were complete within 8 hours of blood collection per the manufacturer. Within 4 minutes of obtaining the blood sample, 10 L of r-TEG solution (consisting of 8% kaolin, human recombinant tissue factor, phospholipids, buffers, and stabilizers) was added to 0.35 mL of whole blood. The resulting specimens were then added to each cup and settings adjusted for the patient's temperature. The r-TEG was then initiated and stopped after reaching complete tracings. All r-TEG parameters were recorded from standard tracings: TEG activated clotting time (ACT, seconds), angle (␣, degrees), coagulation time (K, seconds), maximum amplitude (MA, mm), clot strength (G, dynes/cm 2 ), estimated percent lysis (EPL, %). Primary fibrinolysis (PF) was defined by EPL Ͼ15%, whereas transient fibrinolysis (TF) was defined as the detection of any fibrinolysis by TEG tracing (EPL) Ͻ15% (Hemoscope Corporation, Niles, IL). The various components of the r-TEG tracing are depicted in Figure 1 . Of note, the r value, which is representative of enzymatic clotting factor activation, is represented by TEG-ACT for the r-TEG assay after addition of tissue factor to the kaolin specimen. K is the interval measured from the TEG-ACT to a fixed level of clot firmness or the point that the amplitude of the tracing reaches 20 mm; this reflects thrombin's ability to cleave soluble fibrinogen. The ␣ is the angle between the tangent line drawn from the base horizontal line to the beginning of the cross linking process, measured in degrees, and is affected primarily by the rate of thrombin generation, which directly influences the conversion of fibrinogen to fibrin; thus the lower the angle, the lesser degree of clot formation. The MA, or MA, measures the maximum clot strength, and is the end result of maximal platelet-fibrin interaction via the GPIIb-IIIa receptors, which simulates the end product of coagulation via the platelet plug. G is a computer-generated value, reflecting the complete strength of the clot from the initial thrombin burst through fibrinolysis and is calculated from A (amplitude), which begins just beyond the bifurcation (split point) of the tracing. This is based on a curvilinear relationship: G ϭ (5000 ϫ A)/(100 Ϫ A) (Fig. 2) . Normal clot strength was defined as G between 5.3 and 12.4 dynes/cm 2 (Hemoscope Corporation, Niles, IL). A systematic review of the medical records was conducted to obtain data with regard to (1) demographic characteristics (age, mechanism of injury), (2) anatomic injury severity (ISS), (3) the presence of hypovolemic shock (systolic blood pressure), indices of FIGURE 1. Thrombelastography is performed by adding 0.35 mL of whole blood to a cuvette, to which additional solutions, including human recombinant tissue factor, are added. After adjusting for the patient's temperature, tracings are recorded as a clot begins to form following rotation of the cup. The associated changes in force are transmitted via a pin and torsion wire to a transducer. The resultant tracing captures the viscoelastic properties of blood associated with the clot, from initial activation through thrombolysis (details are given in text).
FIGURE 2.
The TEG G value is a computer-generated measure of clot strength, and is calculated from the amplitude, A, which begins just beyond the bifurcation ("split-point") of the tracing. At this location, G is comprised of both the prior enzymatic contributions to clot formation, as well as those of the platelet due to activation from the thrombin burst. Monitoring of G permits accurate assessment of coagulability.
perfusion: base deficit and lactate, (4) fluids administered and blood products transfused over 6, 12, and 24 hours (crystalloid, RBC, fresh frozen plasma (FFP), cryoprecipitate, apheresis platelets), and (5) coagulation-related measurements (blood pH, body temperature, International Normalized Ratio (INR), partial thromboplastin time (PTT), at emergency department, 6 hours, and 24 hours.
The results of r-TEG analysis were obtained directly from the TEG database stored in the instrument's software, and results were collated and approximated to the nearest time frames of 1 hour, 3 hours, and on arrival in the intensive care unit. Furthermore, we also calculated the time from injury to first evidence of lysis based on the EPL as recorded on the software.
Our massive transfusion protocol during this study required pre-emptive delivery of 4 units of packed RBC's and 2 units of FFP upon activation of the protocol. Subsequently, with every delivery of an additional 4 units of RBC, 2 units of FFP, 1 unit of apheresis platelets, and one 10 pack of cryoprecipitate is provided. At the discretion of the treating team, the blood bank can "double up" on these blood components if requested. All analyses were performed using SAS version 9.1 for Windows (SAS Institute Inc., Cary, NC, 2002 NC, -2003 with PF. C-statistic was used to assess the discriminative power of G value for prediction of fibrinolysis and death. Significance was set at the 0.05 level. This study was approved by the Colorado Multi-institutional Review Board.
RESULTS

General Demographics and Transfusion Requirements
The results of 61 patients who were studied over 14 months are outlined in Table 1 . Of note, 32 (52%) received a massive transfusion (Ͼ10 units/6 h), 15 (25%) were categorized as moderate (5-9 units/6 hours) and 14 (23%) as minimal (Ͻ5 units/6 h). Thirty-one (51%) patients sustained penetrating injuries, whereas 30 (49%) were the result of blunt force mechanisms. Overall, 19 (31%) patients died, of whom 17 (89%) were in the massive transfusion group, with 1 patient in each of the other 2 categories. Table 1 also displays the results of clinical characteristics, resuscitation, laboratory, and conventional coagulation tests for patients in this study categorized by transfusion groups. Interestingly, there was no significant difference between groups in mean age or ISS, initial systolic blood pressure, or temperature, while as expected, transfusion and crystalloid requirements were significantly different, as were differences in base deficit, lactate, and pH. Although hemoglobin and fibrinogen levels were not different at presentation or at subsequent time frames, initial INR and PTT in the emergency department were noted to be significantly different between groups. Table 2 outlines the results of TEG analyses between groups. Of note, although r-TEG ACT was not different between groups, all other TEG values, including ␣ angle, K time, MA, G value, and EPL were significantly different between groups.
Fibrinolysis Analysis
The results for analysis for general demographics, resuscitation, laboratory, and conventional coagulation tests in all patients for the presence of fibrinolysis are outlined in Table 3 . Although PF (EPL Ͼ15%) occurred in 11 patients overall (18%), this finding was present in 34% of those requiring massive transfusions; 7 (64%) of this group sustained penetrating injuries. TF (EPL Ͻ15%) was noted in 28 patients (46%), occurred in all transfusion groups, and was predominately noted with blunt injury mechanisms (18, 64%). Twenty-two patients (36%) failed to display evidence of fibrinolysis. These patients sustained equal numbers of blunt and penetrating injuries. Patients with fibrinolysis trended toward a higher ISS (P ϭ 0.06), were significantly more hypotensive on presentation (P ϭ 0.003), were more hypothermic in the emergency department. (P ϭ 0.002), and received significantly more RBC's (P ϭ 0.002). Of note, patients with fibrinolysis had significantly higher base deficit, serum lactate, lower hemoglobin, lower pH, and higher INR in the emergency department (all P Ͻ 0.0001). In addition, the presence of fibrinolysis was also associated with a depressed fibrinogen at 1 hour (P ϭ 0.0005), as well as a prolonged PTT in the emergency department and at 6 hours (P ϭ 0.01, P ϭ 0.05, respectively). Figure  3 shows the associations of fibrinolysis with death in this study. As noted, there was a progressive, significant increase in mortality based on the degree and presence of fibrinolysis.
The results of TEG analysis of these patients are shown in Table 4 . Virtually, all TEG values were significantly abnormal in all patients at 1 and 3 hours postinjury, although there was no difference noted on arrival in the intensive care unit. The median time to occurrence of PF was 58 minutes, (IQR, 18.2-95.9 minutes) whereas TF occurred within 104 minutes (IQR, 13.0 -1200 minutes).
Logistic Regression Analysis for Prediction of Fibrinolysis and Death
Models were developed to investigate factors predictive of PF based on demographic/injury severity variables, traditional laboratory values, and TEG values. These results are outlined in Table 5 . Of note, of the demographic/injury severity variables, only temperature in the emergency department emerged as marginally predictive (odds ratio ͓OR͔: 0.41, 95% confidence interval ͓CI͔: 0.22-1.14, P ϭ 0.10). In the model for traditional laboratory values, only Figure 4 demonstrates the results of estimated probability of death by the occurrence of PF and G-value at 1 hour postinjury. This demonstrates that for every 1 unit drop in G-value at 1 hour, the risk of PF increased by 30% and death by over 10% (C statistic ϭ 0.87).
DISCUSSION
A uniform approach to the management of ACOT remains elusive. Of primary significance, hemostasis represents a complicated fusion of multiple events involving dynamic interactions of thrombin, fibrinogen, platelets, calcium, and other protein clotting factors. 14, 41, 42 Accordingly, an improved understanding of the underlying physiologic mechanisms driving these interactions will be complicated by multiple factors. Furthermore, recent advances toward our understanding of the cell-based model of coagulation 43, 44 have emphasized the complementary roles of endothelial-based tissue factor release and collagen pathways as potential mechanistic links of hemostasis and systemic shock. 26, 41, 45 Unfortunately, translating this understanding from the laboratory to the clinical arena remains a formidable challenge. Lastly, and perhaps of greatest significance, currently available conventional tests have proven of little use for assessment of coagulation function in the acutely injured patient. 10 -13 Our results demonstrate that r-TEG, a point of care device, provides efficient, real time analysis of coagulation, and clot strength in the trauma patient, from initial thrombin generation through fibrinolysis. Furthermore, r-TEG accurately identified the process of fibrinolysis (primary or transient), in over 64% of patients overall in this study, whereas PF occurred in over one-third of patients who required massive transfusions. Of note, although the presence of PF was significantly associated with all traditional parameters of shock and impaired tissue perfusion, a reduced r-TEG G-value, readily obtained as a measure of clot strength (dynes/cm 2 ), emerged as a rapidly available and significantly predictive test for identification of fibrinolysis and death as early as 1 hour postinjury.
Shock has long been recognized to induce fibrinolysis. In 1904, Nolf produced fibrinolysis by injection of peptone into dogs, noting that shock and fibrinolysis were accentuated by prior hepatectomy. 46, 47 He further suggested that fibrinolysis could be attributed to a substance secreted by the vascular wall, and recognized that fibrinolysis occurred as a consequence of clotting. Sherry et al, in 1959, 48 ushered in the modern era of fibrinolysis, when his group first demonstrated that the process resulted from an activator in the blood, and described the process involving conversion of plasminogen to plasmin. He further suggested that in the presence of a thrombus, the plasminogen would be absorbed to the clot. 49 Astrup and Thorsen 50 introduced the concept of hemostatic balance, reflective of the in vitro relationships of thrombosis and fibrinolysis. Our current understanding of fibrinolysis suggests that plasminogen, a beta globulin, is converted via limited proteolysis to Lys-plasminogen, 50 -53 which has a greater affinity for fibrin, and is more readily activated by urokinase. The physiological activator of plasminogen is believed to be tissue plasminogen activator (t-PA), a serine protease which has a high affinity for fibrin. Fibrinolysis can 24, 30, 31 The end result of these processes is the digestion of fibrin and fibrinogen, resulting in degradation products ("fibrin split products"), which have traditionally been the major method applied clinically for identification of fibrinolysis.
11,54,55 Current conventional methods for evaluation of fibrinolysis have centered on the use of fibrin split products, the D-dimer test, or the euglobulin lysis time, all of which require prolonged time periods for testing, which is clearly not applicable in the trauma setting. Accordingly, these tests are virtually never performed, and the presence of fibrinolysis is usually presumptive in the clinical setting when the operating team recognizes that the patient appears to be rapidly dissolving formed clots in the operative field. TEG, first described by Hartert 56 in 1948, involves a technique of rotational motion resulting in fibrin strands generated in a small cuvette (0.35 mL) of whole blood. The resulting tracing, which is generated by an electronic amplification system, assesses clot strength from initial fibrin formation to clot retraction resulting from fibrinolysis. Of note, TEG is the only single test capable of providing information on the important balance between thrombosis and fibrinolysis. Our previous experience with this device suggests that when the rapid assay is performed via activation with tissue factor, it is best accomplished with noncitrated whole blood. 56 Experiences with the device in our institution, 25, 32, 33 suggest that it is useful for goal-directed management of patients at risk for postinjury coagulopathy. In a recent review of postinjury coagulopathy management, we suggested the potential benefits of goal-directed therapy in this cohort, including potential strategies for component blood replacement via real time, sequential stepwise r-TEG perioperative monitoring of coagulation status. 17 Others 15, 16, 18, 19, [35] [36] [37] 39, 57, 58 have also reported on the usefulness of point of care monitoring of coagulation status. TEG has gained popularity in the management of cardiac surgery patients with postpump coagulopathy, 38, 59 as well as in the management of coagulopathy associated with liver transplantation. 34, 60 Recent experience with the use of TEG in trauma has come from Europe 4, 16, 57, 58, [61] [62] [63] where some centers have used the rotational thromboelastometry (ROTEM) device. Rugeri et al 63 reported on the results of 90 trauma patients managed with ROTEM, and suggested that fibrinolysis was likely present in 25 patients on the basis of a decreased ROTEM clot lysis index, but acknowledged that their study was not designed to investigate fibrinolysis. A more recent European report by Schochl et al, 58 identified only 33 cases of fibrinolysis over 4 years at a busy German Trauma Center. Although they suggested that the gold standard for detection of fibrinolysis is point of care testing, the presence of fibrinolysis in their study was essentially a premortem finding, with an overall mortality of 88%. Whereas they noted that fibrinolysis occurred almost exclusively in severe trauma patients, their results documenting a low frequency of lysis in their trauma population calls into question the sensitivity of the ROTEM device versus the TEG device used in our studies.
Our results show that a progressive increase in the degree of fibrinolysis correlated with all shock parameters and hemorrhagerelated mortality. Although these findings support a mechanistic link of fibrinolysis to the ACOT, others 64, 65 have previously recognized that fibrinolysis is likely important in this process, although docu- 
FIGURE 4.
There was a progressive, significant increased risk of death based on the degree of fibrinolysis and the G value at 1 hour postinjury. Every 1 unit drop in G increased the risk of primary fibrinolysis by 30%, and of death by over 10%.
menting its presence has been elusive. Brohi et al 21, 24 prospectively studied patients after trauma admission and noted that those with significant hypoperfusion (base deficit Յ6) had evidence of coagulopathy as measured by conventional coagulation tests. They also noted that shock was associated with a rise in serum thrombomodulin levels and a decrease in protein C, with associated elevations in t-PA, increased levels of D-dimers, and decreased plasminogen activation inhibitor-1, leading to a "de-inhibition" of fibrinolysis. The authors recognized, however, that conventional coagulation tests were "crude methods of identifying coagulopathy," and went on to suggest that point of care testing might provide more clinically important data in future studies. Furthermore, our previous findings 25 suggesting that early postinjury coagulopathy, which we termed "acute endogenous coagulopathy," could be resistant to the effects of plasma resuscitation due to mechanistic pathways unrelated to factor depletion, could support our current description of an intermediate phase of "transient" fibrinolysis. Because the occurrence of fibrinolysis likely reflects a critical balance between the presence of endogenous t-PA and PA-I, it is conceivable that TF could be responsive to conventional factor replacement, whereas PF likely requires the addition of antifibrinolytic therapy to reverse the lytic process and avoid progression to a diffuse, consumptive state. This is supported by our findings that increasing EPL and decreasing clot strength were associated with a mortality rate in excess of 60% in cases of PF (Figs. 3, 4) . Furthermore, because fibrinolysis is noted to occur at the completion of the TEG tracing, prior sequential TEG values (TEG-ACT, ␣ angle, K time, MA) demonstrating adequate substrate suggest that in many cases, the fibrinolytic state is a direct physiological response to injury, as opposed to a premorbid condition reflecting physiological exhaustion, which is typified by a diffuse, severe hypocoagulable state on the TEG tracing. Accordingly, our current approach involves step-wise goal-directed therapy for specific coagulation deficiencies as noted on the r-TEG tracing, with the addition of antifibrinolytic therapy for those patients demonstrating PF. We believe that the differentiation of PF from such a diffuse hypocoagulable state of physiologic exhaustion is essential for improved survival in this group. Although systemic antifibrinolytic agents are frequently used primarily in elective cardiac procedures, 66 -71 results suggest that transfusion requirements may be substantially reduced. Despite this, to date, there is only 1 small randomized trial evaluating the potential effect of these agents in surgical patients, 72 without conclusive findings. Other ongoing studies, such as the Crash-2 trial 73 may provide additional insights; although the study may be limited by random administration of antifibrinolytic agents to large numbers of trauma patients with significant variations in injury severity and transfusion requirements. Of note, entry criteria allowed for patient enrollment up to 8 hours postinjury. Besides potential difficulties with study design, there are additional limitations due to a lack of definitive diagnosis of fibrinolysis via POC technology.
The distinctive TEG tracing characteristic of PF (Fig. 1 ) should prompt immediate treatment. In the United States, the most commonly used agent is epsilon aminocaproic acid ("Amicar"), a lysine analogue which binds reversibly to the kringle domain of the enzymogen plasminogen, preventing it's activation to plasmin, which can therefore not split fibrin. Other agents available include aprotinin and tranexamic acid. Of note, although definitive studies are lacking, the safety of aprotinin has been questioned due to concerns regarding renal and cardiovascular adverse events. 53, 74 Our preliminary experience suggests that in response to r-TEG proven PF, Amicar (5 g/20 mL), repeated as necessary, may reverse the lytic process and restore hemostasis.
Our study has certain limitations. The data presented represent a secondary analysis of our accumulated experience investigating the usefulness of TEG in our institution for management of postinjury coagulopathy. The findings of significant patterns of fibrinolysis were unexpected, and fibrinolysis was not a primary end point for this investigation. Accordingly, the documentation of fibrinolysis represents selected points in time based on tests ordered by the treating team in a busy perioperative management scheme. Furthermore, in most cases, we did not obtain r-TEG studies immediately on arrival of patients in the emergency department, precluding definitive conclusions regarding the actual timing of onset of fibrinolysis in the injured patient. Finally, most r-TEG values in this study were obtained after the initiation of resuscitation efforts; hence, the impact of such resuscitation on fibrinolysis remains unknown.
In sum, our results confirm the existence of fibrinolysis as detected by TEG in severely injured patients. Fibrinolysis occurs early after injury, and is associated with massive transfusion requirements, coagulopathy, and hemorrhage-related death. Future investigations are required to better ascertain the timing of onset of fibrinolysis, with the potential for early diagnosis and treatment.
Discussions
DR. DAVID HOYT (ORANGE, CA): The current article is important because it takes comprehensive point-of-care testing using rapid thromboelastography to a new level and describes the importance of PF and the risks associated with it. The findings suggest that there is a specific group of patients with a primary fibrinolytic state that occurs on presentation, and is associated with the sickest patients following injury.
This observation is particularly important because it could be a potential target for intervention at a time when our traditional thinking suggests that fibrinolysis inhibition might be potentially dangerous and might actually enhance coagulopathy.
I have a few questions. First, what do you think is the cause of this state? Is this just the natural end of massive consumptive coagulation due to bleeding leading to a normal triggering of the fibrinolytic state and, therefore, is this just reflecting physiologic exhaustion in these very sick patients? Second, what therapeutic interventions might be possible in this subgroup and how would one monitor the completeness of the therapeutic effect?
Finally, how practical is TEG as a measurement to detect this complex process in the average trauma center? Will it be important in identifying a primary fibrinolytic state and will this then validate the use of this mode of testing?
DR. NORMAN MCSWAIN (NEW ORLEANS, LA): As you know, there has been a major shift in many trauma centers across the country in the last 2 or 3 years from over transfusing with large volumes of crystalloid to the use of plasma and plasma like products for resuscitation and minimal to no use of crystalloid. I have 3 questions (1) did you analyze your patients based on the amount of plasma replaced versus the amount of crystalloid replaced? (2) Do you think that would produce any difference in your outcome? And, (3) did your patients experience plasma clotting factor loss, or was this an intrinsic increase in coagulopathy secondary to tissue trauma? DR. CHARLES LUCAS (DETROIT, MI): We know that the TEG is really a surrogate for measuring fibrinolytic activity. Although it takes a couple of hours to measure the split products, did you actually measure the split products, or D-dimer, to show that the surrogate test is really looking at fibrinolytic activity? DR. TIM BILLIAR (PITTSBURGH, PA): My questions relate to the mechanism. Studies in this area have suggested that a combination of reduced perfusion and a significant degree of tissue injury are required for early trauma-induced coagulopathy. Could you determine in your own studies, on the clinical side, whether you see evidence of this?
Could you also tell us a little bit more about the mechanism of death in these patients? You mentioned that many of them bled to death. We know there is a connection between the coagulation system, the immune system, and complement. Was there an incidence of increased death late due to immune failure or inflammation-induced end organ damage? DR. COURTNEY M. TOWNSEND (GALVESTON, TX): Has your test, in fact, identified those patients who are already "Wiggers Preps" by the time they arrived in the emergency room? DR. LARRY DIEBEL (DETROIT, MI): The test was performed at 37°to make it more physiologic relevant for what is happening in the patient. Should this test be repeated at the temperature at which the patient arrives? DR. DONALD TRUNKEY (PORTLAND, OR): There is a great deal of evidence that the response after injury is genetically determined. Have you done any studies to show that the third of the patients who develop fibrinolysis in the severe group were responding differently than the other two-thirds that did not develop it?
CLOSING DISCUSSANT
DR. JEFFRY KASHUK (HERSHEY, PA): Dr. Hoyt asked, what do we think the cause of this state might be? Is this just a natural end of massive consumptive coagulopathy due to bleeding leading to a normal triggering of the fibrinolytic state, or is this really reflecting physiologic exhaustion, if you will, in the sickest patients? We think that fibrinolysis is a normal physiologic response to thrombosis that may be critical for survival under shock and low-flow states. And in fact, it is a teleologic survival mechanism.
The degree of fibrinolysis is probably affected by local injury patterns and likely reflects a balance between endogenous TPA and plasminogen activation inhibitor, plasminogen activation inhibitor 1, as well as many other factors. Perhaps the essence of your question, Dr. Hoyt, is really, what is driving the shift in this balance in the injured patient?
I think, we are just beginning to delve into this very important question. Certainly, tissue factor release is integral. We know the levels of tissue factor vary significantly in the body, and accordingly, there are probably local differences in fibrinolysis in the human being.
The beauty of TEG is that it is a dynamic test that reflects a dynamic process in vivo. This means that when we see fibrinolysis, if the earlier portions of the tracing are intact, then adequate substrate is present, suggesting that fibrinolysis is not related to physiologic exhaustion, but more likely related to factors associated with shock at the endothelial level.
Furthermore, when we observed consumptive coagulopathy, it followed PF, suggesting that the lytic process is driving the consumption of clotting factors, rather than the reverse.
We also think the fact that this is occurring quite early means that there is, perhaps, a window of opportunity for therapy before the consumptive state occurs.
Dr. Hoyt also asked about what therapeutic interventions might be possible in this subgroup and how one could monitor the completeness of the therapeutic effect?
We think that therapeutic inventions are dynamic; based on successive TEG tracings, and one must wait until the end of the TEG tracing to identify fibrinolysis. When it is primary, it is clearly identified, we think, this would be an indication for antifibrinolytics, as opposed to disseminated intravascular coagulation processes, as is found in malignancy, where secondary fibrinolysis occurs in the face of a hypercoagulable state.
The beauty of the point-of-care device is that the TEG tracing is evolving whereas the patient is undergoing treatment. Therefore, the changes in the various phases of the tracing encountered can be treated prior to identification of the lytic state. We also believe that such an approach-and this will partially answer Dr. McSwain's question-can allow for specific factor replacement therapy, rather than presumptive administration of multiple blood products, allowing for goal directed therapy for specific coagulation defects, rather than continued presumptive resuscitation. Furthermore, we noticed no obvious effects of the amount of crystalloid administered vis-à-vis fibrinolysis during our study, as our protocol was unchanged, as was our use of plasma, which, on initial resuscitation, was based on a 1:2 ratio, but continued resuscitation was guided by both conventional and point of care monitoring of coagulation function. We certainly agree that tissue injury, as well as shock, likely contribute to the fibrinolysis, which certainly eventuates in clotting factor deficiency.
In answer to Dr. Hoyt's question asking how practical TEG is in detect the complex process in the average trauma center, and whether the importance of identifying PF validates this as a valuable mode of testing? We Believe, Dr. Hoyt, that TEG has an important role for identification as well as quantifying the degree of fibrinolysis, and that, for the first time, it seems to be the only test that is rapidly available for this purpose. Furthermore, the rapid assay, with the addition of tissue factor, allows for the speed necessary to make the test relevant in the injured patient.
As you correctly point out, hemostasis is a complex process, and TEG provides us with a blueprint of the clotting, based on the cell-based model of coagulation to help decipher this.
Lastly, President Trunkey, the frequency of fibrinolysis in our study was quite surprising. Its early identification and treatment could be very important going forward. Although some might suggest that fibrinolysis alone would validate the usefulness of the TEG, we think that point of care testing has the additional potential benefit to guide component therapy. We agree that future genetic studies might suggest phenotypes that are specifically more likely to develop fibrinolysis, but have not, to this point, studied this.
Dr. Lucas we have not measured split products or D-dimers to correlate with the TEG, and agree this would be useful. This would have to be part of a prospective analysis given the significant time delay to obtain such results in the bleeding trauma patient. There are animal studies to suggest that it correlates well, as well as some of the studies by Brohi et al, which have verified the presence of increased TPA, fibrin split products, and so on, in the injured patient.
Dr. Billiar regarding mechanisms, we totally agree that the importance of low perfusion and tissue injury is particularly critical to understanding this process. Clearly, we identified in this study that shock and tissue injury correlate with the presence and degree of fibrinolysis as identified by TEG.
As far as the mechanisms of death, I think our numbers are too small to draw any absolute conclusions. What we can say is that death strongly correlated with the degree of fibrinolysis and shock in this cohort. Furthermore, although we certainly agree with you that there is significant cross-talk between the inflammatory system and coagulation mechanisms; in this study, virtually all of the deaths were associated with exsanguinations or coagulopathy as opposed to late multiple organ failure.
Dr. Townsend thank you for your question as to whether these patients were essentially "Wigger's Preps" or close to dead when they hit the emergency department. We noted that in some patients, a consumptive phase tracing on the TEG, (suggesting a severe depletion of clotting factors after the fibrinolytic state), may indeed be associated with a premorbid state. However, many of these patients likely possess clotting factors and yet go on to display fibrinolysis very early. In some of these cases, we successfully used antifibrinolytics, such as Amicar. Certainly, such an approach will need to be addressed more closely in the future.
Dr. Diebel asked about the temperature of the test. In fact, the TEG can be adjusted to the patient's temperature, which is a tremendous benefit over conventional coagulation testing, which, as we all know, is done at 37°.
